Role of an inverted CCAAT element: In human topoisomerase IIα gene expression in ICRF-187-sensitive and -resistant CEM leukemic cells

Molecular Pharmacology

Volumn 59, Issue 2, 2001, Pages 203-211

  Morgan, Susan E ^a,b   Beck, William T ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN; DNA TOPOISOMERASE; RAZOXANE;

ARTICLE; CELL PROLIFERATION; DNA CLEAVAGE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA INTERACTION; RECEPTOR GENE; RECEPTOR UPREGULATION; SISTER CHROMATID; TRANSCRIPTION REGULATION;

EID: 0035133548     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.59.2.203     Document Type: Article

References (40)

1. Chromosome assembly in-vitro: Topoisomerase II is required for condensation
2. Cell-cycle regulation of the DNA topoisomerase IIα promoter is mediated by proximal CCAAT boxes: Possible involvement of acetylation
3. Bis (2, 6-dioxoplperazines), catalytic inhibitors of DNA topoisomerase II, as molecular probes, cardioprotectors and antitumor drugs
4. Resistance of mammalian tumor cells to inhibitors of DNA topoisomerase II
5. Tumor cell resistance to DNA topoisomerase II inhibitors: New developments
6. c-Myb trans-activates the human DNA topoisomerase IIalpha gene promoter
7. Mechanistic aspects of type-II topoisomerases
8. Nonintercalative antitumor drugs interfere with the breakage reunion reaction of mammalian DNA topoisomerase II
9. Characterization of the cDNA encoding a protein binding to the major histocompatibility complex class II Y box
10. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II
11. Murine transgenic cells lacking DNA topoisomerase II beta are resistant to acridines and mitoxantrone: Analysis of cytotoxicity and cleavable complex formation
12. Evidence for repressional role of an inverted CCAAT box in cell cycle-dependent transcription of the human DNA topoisomerase IIα gene
13. Topoisomerase II alpha promoter trans-activation early in monocytic differentiation of HL-60 human leukemia cells
14. The role of an inverted CCAAT element in transcriptional activation of the human DNA topoisomerase IIα gene by heat shock
15. Differential expression of DNA topolsomerases I and II during the eukaryotic cell cycle
16. Evaluation of a potential regulatory role for inverted CCAAT boxes in the human topoismerase IIα promoter
17. Cloning and characterization of the 5′ flanking region of the human tepoisomerase IIα gene
18. Co-evolution from yeast to mouse: cDNA cloning of the two NF-Y (CP-1/CBF) subunits
19. Regulation of the human topoisomerase IIα gene promoter in confluence-arrested cells
20. Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24
21. A novel mechanism of cell killing by antitopoisomerase II bisdioxoplperazines
22. DNA topoisomerase IIα gene expression under transcriptional control in etoposide/teniposide-resistant human cancer cells
23. Intronexon organization of the NF-Y genes. Tissue-specific splicing modifies an activation domain
24. Three different palypeptides are necessary for DNA binding of the mammalian heteromeric CCAAT binding factor
25. Monoclonal antibodies to NF-Y define its function in MHC class II and albumin gene transcription
26. SUMO-1 conjugation to human DNA topoisomerase II isozymes
27. Down-regulation of topoisomerase IIα in CEM cells selected for merbarone resistance is associated with reduced expression of Sp3
28. Heterogeneous expression of DNA tepoisomerase IIα isoforms in tumor cell lines
29. 2/M checkpoint and apoptotic responses
30. Antitopoisomerase drug action and resistance
31. Mechanism of action of topoisomerase II-targeted antineoplastic drugs
32. CCAAT-box binding protein NF-Y (CBF, CP1) recognizes the minor groove and distorts DNA
33. A family of human CCAATbox-binding proteins active in transcription and DNA replication: Cloning and expression of multiple cDNAs
34. Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle
35. Structural and functional analysis of the control region of the human DNA topoisomerase IIα gene in drug-resistant cells
36. Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-q22
37. Decreased CP-1 (NF-Y) activity results in transcriptional down-regulation of topoismerase IIα in a doxorubicin-resistant variant of human multiple myeloma RPMI 8226
38. Inhibition of DNA topoisomerase IIα gene expression by the p53 tumor suppressor
39. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells
40. DNA topoisomerase II beta and neural development